NCT00082810 2018-11-01
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
7 trialsNCT00052728 2013-06-19
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00049114 2013-06-06
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077363 2013-02-27
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00050141 2013-02-01
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00054470 2012-06-29
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT00210028 2006-11-14
Study Assessing Efficacy of ZARNESTRAâ„¢ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer
Institut Claudius Regaud
Phase 2 Terminated